# Arjun Goyal

> Arjun Goyal is a Series A investor at Affini-T Therapeutics backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Affini-T Therapeutics](https://shizune.co/investors/profile/affini-t-therapeutics)
- Location: Boston, United States
- Total investments: 12
- Last investment: Aug 2024
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/drarjungoyal/

Arjun Goyal is a Co-Founder and Managing Director at Vida Ventures and a Co-founder at Affini-T Therapeutics. He has an MBA from Harvard Business School and University of Cambridge, a bachelor's degree from University of Oxford and University of Melbourne.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 58% |
| Health Care | 4 | 33% |
| Therapeutics | 4 | 33% |
| Medical | 3 | 25% |
| Pharmaceutical | 3 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 33% |
| Series B | 4 | 33% |
| Series C | 2 | 17% |
| Series D | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Halda Therapeutics | Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $126M | Series B | Aug 12, 2024 |  |
| Third Arc Bio | Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $165M | Series A | Jul 23, 2024 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $150M | Series C | Jul 16, 2024 |  |
| Alterome Therapeutics | Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $132M | Series B | Apr 03, 2024 |  |
| Quanta Therapeutics | Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $50.7M | Series D | May 22, 2023 |  |
| Affini-T Therapeutics | Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-celltherapies designed to eradicate tumors. | $175M | Venture - Series Unknown | Mar 22, 2022 |  |
| Alterome Therapeutics | Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $64M | Series A | Jan 19, 2022 |  |
| Quanta Therapeutics | Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $60M | Series C | Oct 26, 2021 |  |
| Centessa Pharmaceuticals | Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by acentralized infrastructure and the Centessa management team. | $250M | Series A | Feb 16, 2021 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $162M | Series B | Jan 07, 2021 |  |

10 of 12 investments shown.

## Co-investors
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 6 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 5 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 5 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 5 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 4 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 4 deals together

## About Affini-T Therapeutics

VC Fund · Watertown, United States

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-celltherapies designed to eradicate tumors.

5 contacts available at Affini-T Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Arjun Goyal | Co-founder | https://shizune.co/investors/profile/arjun-goyal |
| Jak Knowles | Co-Founder, President and Chief Executive Officer | https://shizune.co/investors/profile/jak-knowles |
| Kathy Yi | Chief Operating Officer | https://shizune.co/investors/profile/kathy-yi |
| Kim Nguyen | Chief Technical Officer | https://shizune.co/investors/profile/kim-nguyen-d1b6 |
| Loic Vincent | CSO | https://shizune.co/investors/profile/loic-vincent |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Arjun Goyal invest in?

Arjun Goyal invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Arjun Goyal last invest?

The most recent investment recorded for Arjun Goyal closed in Aug 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co